| Name | Title | Contact Details |
|---|---|---|
Sujin Key |
Director, Clinical Supply Chain and CMC Ops | Profile |
Courtney Grafe |
Director Talent Acquisition | Profile |
Jessica Ferreyra |
Chief Of Staff | Profile |
Brian Muma |
Vice President, Human Resources | Profile |
Roche NimbleGen is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
iCo Therapeutics Inc. is a Vancouver-based development company focused on in-licensing drugs with clinical history redosing or reformulating for new or expanded indications. iCo has exclusive worldwide rights to three products. iCo-007, a second generation antisense candidate licensed from Isis Pharmaceuticals, is currently in a Phase I trial in Diabetic Macular Edema patients with compelling early data. iCo-008 is a human monoclonal antibody targeting eotaxin-1 with Phase II clinical history, licensed from AstraZeneca/MedImmune. iCo-009 is a proprietary oral formulation of amphotericin B licensed from the University of British Columbia.
We are harnessing the #gut brain axis & the #CNS to develop a new class of therapeutics for people with neurological diseases & disorders
Geltor is the bio-design company that makes the world`s most advanced proteins for consumers, with a focus on unique functionality and sustainability.
Intracel Resources is a Frederick, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.